In January of this year, MAP Pharma entered into a collaboration with Allergan Inc. (AGN) within the U.S. for Levadex in a deal valued at $157 million - $60 million up-front payment and up to $97 million in additional payments upon meeting certain regulatory milestones. Pursuant to the terms of the agreement, MAP Pharma granted Allergan a co-exclusive license to market and promote Levadex to neurologists and pain specialists in the United States.